Adam DuVall

Dr. Adam DuVall is an Assistant Professor at the University of Chicago in the Department of Medicine-Hematology and Oncology. His research focuses on hematologic malignancies, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and TP53 mutations, with an emphasis on targeted therapies and healthcare disparities.

• Institution: University of Chicago
• Department: Medicine-Hematology and Oncology
• Academic Rank: Assistant Professor

Dr. DuVall's research explores:

• Molecular mechanisms in RUNX1-familial platelet disorder
• Outcomes of TP53-mutated leukemias
• Role of FLT3 and IDH inhibitors in ALL
• Healthcare disparities in AML treatment
• Costs of care for relapsed/refractory leukemias
• Socioeconomic determinants in cancer biology

His recent publications (2024-2025) span hematology, oncology, and pharmacology, with collaborative studies on stem cell transplantation, therapeutic regimens, and psychosocial interventions for cancer survivors. Key themes include precision medicine, healthcare equity, and clinical trial outcomes.

Dr. DuVall collaborates extensively with oncology teams at the University of Chicago and multi-institutional consortia, focusing on improving treatment strategies and addressing disparities in hematologic cancers.